HIF-1α genetic variants and protein expression confer the susceptibility and prognosis of gliomas

NeuroMolecular Medicine

Volumn 16, Issue 3, 2014, Pages 578-586

  Yi, Liang ^a   Hou, Xuwei ^b   Zhou, Ji ^a   Xu, Lunshan ^a   Ouyang, Qing ^a   Liang, Hong ^a   Zheng, Zhaocong ^c   Chen, Hongjie ^c   Xu, Minhui ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Gliomas; Hypoxia inducible factor 1 ; Polymorphism; Prognosis; Risk

Indexed keywords

HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA; TUMOR MARKER; TUMOR PROTEIN;

ADULT; BRAIN NEOPLASMS; CASE CONTROL STUDY; CELL DIVISION; CELL MOTION; CHINA; FEMALE; GENE SILENCING; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GLIOMA; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE; TUMOR INVASION;

ADULT; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CHINA; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84906091778     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-014-8310-1     Document Type: Article

References (54)

1. Abraham, S., Hu, N., & Jensen, R. (2012). Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: comparison with established biomarkers and preoperative UCSF low-grade scoring system. Journal of Neuro-oncology, 108(3), 459-468.
2. Aebersold, D. M., et al. (2001). Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research, 61(7), 2911-2916.
3. Alves, L. R., et al. (2012). High HIF-1alpha expression genotypes increase odds ratio of oral cancer. Head & Neck Oncology, 4, 87.
4. Bos, R., et al. (2001). Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. Journal of the National Cancer Institute, 93(4), 309-314.
5. Bos, R., et al. (2003). Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer, 97(6), 1573-1581.
6. Caggana, M., et al. (2001). Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiology, Biomarkers and Prevention, 10(4), 355-360.
7. Carpentier, C., et al. (2007). Association of telomerase gene hTERT polymorphism and malignant gliomas. Journal of Neuro-oncology, 84(3), 249-253.
8. Ceramilac, A., & Berger, S. (1984). Prognosis in cerebral gliomas. Glas Srp Akad Nauka Med, 36, 45-49.
9. Chen, M. K., et al. (2009). The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. Oral Oncology, 45(12), e222-e226.
10. Chen, H. J., et al. (2012). The effect of galectin-3 genetic variants on the susceptibility and prognosis of gliomas in a Chinese population. Neuroscience Letters, 518(1), 1-4.
11. Chun, Y. S., Kim, M. S., & Park, J. W. (2002). Oxygen-dependent and -independent regulation of HIF-1alpha. Journal of Korean Medical Science, 17(5), 581-588.
12. Clifford, S. C., et al. (2001). The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene, 20(36), 5067-5074.
13. El-Zein, R., et al. (2001). Risk assessment for developing gliomas: A comparison of two cytogenetic approaches. Mutation Research, 490(1), 35-44.
14. Erpolat, O. P., et al. (2013). Hypoxia-related molecules HIF-1alpha, CA9, and osteopontin: Predictors of survival in patients with high-grade glioma. Strahlentherapie und Onkologie, 189(2), 147-154.
15. Fan, W., et al. (2011). Single nucleotide polymorphisms of matrix metallopeptidase 3 and risk of gliomas in a Chinese han population. Molecular carcinogenesis, 51, E1-E10.
16. Fang, J., et al. (2001). HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Research, 61(15), 5731-5735.
17. Galanis, A., et al. (2008). Reactive oxygen species and HIF-1 signalling in cancer. Cancer Letters, 266(1), 12-20.
18. He, P., et al. (2013). The association between hypoxia-inducible factor-1 alpha gene C1772T polymorphism and cancer risk: A meta-analysis of 37 case-control studies. PLoS ONE, 8(12), e83441.
19. Hebert, C., et al. (2006). Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Molecular Cancer, 5, 3.
20. Hill, R. P., Marie-Egyptienne, D. T., & Hedley, D. W. (2009). Cancer stem cells, hypoxia and metastasis. Seminars in Radiation Oncology, 19(2), 106-111.
21. Hiraga, T., et al. (2007). Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Research, 67(9), 4157-4163.
22. Hsieh, C. H., et al. (2010). Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity. Oncology Reports, 24(6), 1629-1636.
23. Hu, Y. L., et al. (2012). Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Research, 72(7), 1773-1783.
24. Jha, P., et al. (2011). TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Experimental and Molecular Pathology, 90(2), 167-172.
25. Kilburn, L., et al. (2010). Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. Cancer, 116(9), 2242-2249.
26. Kim, H. O., et al. (2008). The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer. Oncology Reports, 20(5), 1181-1187.
27. Konac, E., et al. (2007). An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detection and Prevention, 31(2), 102-109.
28. Kondratieva, T. V., et al. (2000). L-MYC and GSTM1 polymorphisms are associated with unfavourable clinical parameters of gliomas. Journal of Experimental & Clinical Cancer Research, 19(2), 197-200.
29. Kreth, F. W., et al. (1997). The risk of interstitial radiotherapy of low-grade gliomas. Radiotherapy and Oncology, 43(3), 253-260.
30. Lee, S. J., et al. (2011). No association of the hypoxia-inducible factor-1alpha gene polymorphisms with survival in patients with colorectal cancer. Medical Oncology, 28(4), 1032-1037.
31. Li, P., et al. (2012). Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. Asian Journal of Andrology, 14(6), 864-869.
32. Liu, J., & Zhang, H. X. (2013). 1790 G/A polymorphism, but not 1772 C/T polymorphism, is significantly associated with cancers: an update study. Gene, 523(1), 58-63.
33. Lopez-Lazaro, M. (2009). Role of oxygen in cancer: Looking beyond hypoxia. Anti-Cancer Agents in Medicinal Chemistry, 9(5), 517-525.
34. McClung, H. M., et al. (2007). SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neuroscience Letters, 419(2), 172-177.
35. McKean-Cowdin, R., et al. (2009). Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiology, Biomarkers and Prevention, 18(4), 1118-1126.
36. Mendichovszky, I., & Jackson, A. (2011). Imaging hypoxia in gliomas. British Journal of Radiology., 84(2), S145-S158.
37. Musicco, M., et al. (1988). A case-control study of brain gliomas and occupational exposure to chemical carcinogens: The risk to farmers. American Journal of Epidemiology, 128(4), 778-785.
38. Nava-Salazar, S., et al. (2011). Polymorphisms in the hypoxia-inducible factor 1 alpha gene in Mexican patients with preeclampsia: A case-control study. BMC Research Notes, 4, 68.
39. Pennacchietti, S., et al. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 3(4), 347-361.
40. Pinto, G. R., et al. (2009). Association study of an epidermal growth factor gene functional polymorphism with the risk and prognosis of gliomas in Brazil. International Journal of Biological Markers, 24(4), 277-281.
41. Putra, A. C., et al. (2013). Genetic variations in detoxification enzymes and HIF-1alpha in Japanese patients with COPD. The Clinical Respiratory Journal, 7(1), 7-15.
42. Raheja, L. F., et al. (2011). Hypoxic regulation of mesenchymal stem cell migration: The role of RhoA and HIF-1alpha. Cell Biology International, 35(10), 981-989.
43. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 3(10), 721-732.
44. Semenza, G. L. (2010). HIF-1: Upstream and downstream of cancer metabolism. Current Opinion in Genetics & Development, 20(1), 51-56.
45. Smith, J. S., et al. (2001). PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. Journal of the National Cancer Institute, 93(16), 1246-1256.
46. Tanimoto, K., et al. (2003). Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis, 24(11), 1779-1783.
47. Vainrib, M., et al. (2012). HIF1A C1772T polymorphism leads to HIF-1alpha mRNA overexpression in prostate cancer patients. Cancer Biology & Therapy, 13(9), 720-726.
48. Wang, X. W., et al. (2012). Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas. Cancer, 119, 806-813.
49. Wang, X., et al. (2011). Polymorphisms in the hypoxia-inducible factor-1alpha gene confer susceptibility to pancreatic cancer. Cancer Biology & Therapy, 12(5), 383-387.
50. Welsh, S. J., & Powis, G. (2003). Hypoxia inducible factor as a cancer drug target. Current Cancer Drug Targets, 3(6), 391-405.
51. Xu, L. F., et al. (2013). Effects of hypoxia-inducible factor-1alpha silencing on the proliferation of CBRH-7919 hepatoma cells. World Journal of Gastroenterology, 19(11), 1749-1759.
52. Yeung, T. M., Gandhi, S. C., & Bodmer, W. F. (2011). Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proceedings of the National Academy of Sciences USA, 108(11), 4382-4387.
53. Zhao, T., et al. (2009). Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: A meta-analysis. Journal of Experimental & Clinical Cancer Research, 28, 159.
54. Zhou, C., et al. (2013). MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1. PLoS ONE, 8(5), e63142.